Table 3.

HRs and 95% CIs for the risk of incident cancers in people with type II diabetes

HR (95% CI)P
Unadjusted analyses
 Log-transformed VAP-1 (ng/mL)5.64 (2.20–14.51)<0.0001
 VAP-1 tertile
  Lowest, <622 ng/mL1
  Middle, 622–780 ng/mL1.00 (0.53–1.89)1.0
  Highest, ≥780 ng/mL1.97 (1.12–3.47)0.018
 CKD2.54 (1.56–4.11)<0.0001
 Proteinuria2.20 (1.26–3.69)0.005
Adjusted analysesa
 Model 1b
  Log-transformed VAP-1 (ng/mL)5.07 (1.90–16.08)0.002
  CKD2.34 (1.24–4.44)0.009
  Proteinuria1.53 (0.78–3.02)0.220
 Model 2c
  Log-transformed VAP-1 (ng/mL)6.79 (2.03–22.67)0.002
  CKD2.31 (1.19–4.48)0.013
  Proteinuria1.51 (0.74–3.08)0.3
 Model 3b
  VAP-1 tertile
   Lowest, <622 ng/mL1
   Middle, 622–780 ng/mL1.15 (0.53–2.48)0.732
   Highest, ≥780 ng/mL2.34 (1.11–4.91)0.025
  CKD2.33 (1.23–4.41)0.010
  Proteinuria1.59 (0.81–3.12)0.173
 Model 4c
  VAP-1 tertile
   Lowest, <622 ng/mL1
   Middle, 622–780 ng/mL1.21 (0.53–2.76)0.7
   Highest, ≥780 ng/mL2.95 (1.31–6.63)0.009
  CKD2.29 (1.18–4.44)0.015
  Proteinuria1.53 (0.76–3.08)0.2

NOTE: Bold values signify statistically significant estimates (P < 0.05).

  • aSerum VAP-1, CKD, and proteinuria were all included in adjusted models.

  • bFurther adjusted for age, gender, smoking, fasting plasma glucose, postprandial plasma glucose, and HbA1c.

  • cFurther adjusted for age, gender, smoking, fasting plasma glucose, postprandial plasma glucose, HbA1c, body mass index, hypertension, duration of diabetes, total cholesterol, triglyceride, and medications at enrollment (e.g., sulfonylureas, biguanides, thiazolidinediones, insulin, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, statins).